JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis-Reference-Cited by-同舟云学术

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis

Published:2013-03-26 Issue:3 Volume:8 Page:e59791
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Barosi Giovanni,Poletto Valentina,Massa Margherita,Campanelli Rita,Villani Laura,Bonetti Elisa,Viarengo Gianluca,Catarsi Paolo,Klersy Catherine,Rosti Vittorio

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. One thousand patients with primary myelofibrosis: the mayo clinic experience;A Tefferi;Mayo Clin Proc,2012

2. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis;G Barosi;Blood,2007

3. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;F Cervantes;Blood,2009

4. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis;PJ Campbell;Blood,2006

5. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates;A Tefferi;Br J Haematol,2005

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms;Clinical Laboratory;2021

2. Prognostic models in the myeloproliferative neoplasms;Blood Reviews;2020-07

3. Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular;Hematology, Transfusion and Cell Therapy;2019-07

4. Genetics, prognosis, and transplantation for myelofibrosis;Advances in Cell and Gene Therapy;2018-10-18

5. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?;Biology of Blood and Marrow Transplantation;2018-04